Cenix BioScience Expands Operations to U.S.

Share Article

Cenix BioScience, a leading discovery-stage CRO and technology developer specialized in advanced RNAi screening, microRNA modulation and high content phenotyping, today announced that it is expanding its operations by establishing a new subsidiary in the United States.

News Image

Cenix BioScience, a leading discovery-stage CRO and technology developer specialized in advanced RNAi screening, microRNA modulation and high content phenotyping, today announced that it is expanding its operations by establishing a new subsidiary in the United States.

The new corporation, named Cenix BioScience USA, Inc., is now being set-up in the Minneapolis/St. Paul area of Minnesota as a wholly owned subsidiary of its German parent. The new operation will gradually integrate top management, business development and marketing functions, as well as major new R&D capabilities to extend and complement those long established in Dresden, Germany, and recently added in Beerse, Belgium. As such, this important new step in the company’s ongoing growth and diversification will further broaden the scope of Cenix activities, while also facilitating closer interactions with North American partners from coast to coast.

“Through our many activities with North American partners over the years, we have often been asked when we would expand Cenix across the Atlantic, and so, that time has finally come,” said Dr. Christophe Echeverri, CEO/CSO of Cenix. “We are particularly excited to have the opportunity to combine our existing expertise, which we have built-up and refined over 12 years of intensive discovery work alongside many top industrial and academic partners, with the world-class know-how, cutting-edge capabilities and deep resources available in the Twin Cities region and beyond.”

Cenix will continue to strengthen its leading expertise in advanced applications of RNAi and miRNA modulation combined with high content predictive pharmacology, helping its clients, and particularly large pharmaceutical companies with ever-tighter budgets, in refocusing their discovery efforts to drive more cost-effective, innovative and reliable high-impact R&D.

Dr. Echeverri, continuing in his duties as CEO/CSO of Cenix globally, will now be based primarily in Minneapolis, where he is leading the design and build-up of Cenix USA. This will include a brand new team, as existing Cenix operations in Germany and Belgium will continue largely unchanged, with Dr. Birte Sönnichsen, long-time Cenix COO, taking on Co-Managing Director duties for the Dresden operation.

“We’ve talked about doing this for a long time, so with RNAi and miRNA modulation having become such central contributors to virtually all discovery pipelines, we now have many possible opportunities to launch exciting new diversification initiatives.” noted Dr. Echeverri.

Further details of the U.S.-based activities will be announced over the coming months.

About Cenix

Cenix BioScience conducts contract research and technology development focused on cell-based and in vivo applications of RNA interference (RNAi), miRNA modulation and high content phenotyping to accelerate target discovery, target validation, and the non-clinical development of novel drug candidates. Since its inception in 1999, Cenix has built up leading scientific and commercial track records, successfully advancing drug discovery and development programs for numerous industry and academic partners in a wide range of disease fields. This success is anchored in the consistent application of scientific and technical best practices in fully customized, multi-staged projects designed to offer maximal strategic value with carefully minimized risk and full data transparency. For more information, please visit the company’s web site: http://www.cenix.com/

Contact

Public Relations, Cenix BioScience USA, Inc.
email: inc(at)cenix(dot)com

Cenix and the Cenix BioScience logo are registered trademarks owned by Cenix BioScience GmbH in the U.S. and other countries.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Public Relations
Visit website

Media